Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 5:2 diet melt fat from your liver?

NCT ID NCT04795973

Disease control Sponsor: Beijing Chao Yang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at whether an 8-week 5:2 intermittent fasting diet could help people with fatty liver disease. Eighty adults with excess liver fat followed the diet, eating normally for 5 days and restricting calories to 500 kcal on 2 non-consecutive days each week. Researchers measured changes in liver fat, body weight, and metabolic health markers before and after the diet.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
5:2 intermittent fasting diet
What this could lead to
If successful, this diet approach could offer a simple, drug-free way to reduce liver fat and improve metabolic health in people with fatty liver disease.
What could go wrong
This is a small, completed study without a control group, so results may not be definitive. The diet requires strict adherence and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Sep 2020

Finished

Apr 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * hepatic fat content (HFC) \> 5.0% evaluated by upper abdominal MRI proton density fat fraction (MRI-PDFF) examinations * age ≥ 18 years * body mass index (BMI) ≥ 18.5 kg/m2 * stable body weight (change \< ± 10% of body weight) during the last 3 months Exclusion Criteria: * plasma aspartate aminotransferase (AST) and alanine amino-transferase (ALT) levels exceeded 2.5 times of the upper limit of normal * fasting blood glucose (FBG) levels ≥ 7.0 mmol/L or glycated hemoglobin A1c (HbA1c) ≥ 6.5% * with type 1 or type 2 diabetes * with heart disease * with other hepatic disease (excluding FLD) * with renal disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatty liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fatty liver disease Insulin Resistance metabolic disease metabolic dysfunction-associated steatotic liver disease Norum disease thyroid hormone resistance syndrome Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

In patients with FLD Metabolic parameters Sensitivity to thyroid hormones

Contacts and locations

Locations

  • Beijing Chao-yang Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.